Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas.

ABSTRACT:

Abstract

Epstein-Barr virus (EBV) is associated with a diverse range of lymphomas. EBV-specific T-cell (EBVST) infusions have shown promise in safety and clinical effectiveness in treating EBV-associated lymphomas; however, not all patients respond to T-cell immunotherapies. To identify EBV antigen-specific antibody responses associated with clinical outcomes, we comprehensively characterized antibody responses to the complete EBV proteome using a custom protein microarray in 56 patients with EBV-associated lymphoma who received EBVST infusions in phase 1 clinical trials. Responders (nonprogressors) and nonresponders (progressors) had distinct antibody profiles against EBV. Twenty-five immunoglobulin G (IgG) antibodies were significantly elevated in higher levels in nonresponders t

SUBMITTER: Sarathkumara YD 

PROVIDER: S-EPMC11995064 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature